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Acidic macromolecules inhibit calcium oxalate nucleation,
growth, aggregation and attachment to cells in vitro. To test
for such an effect in vivo we used osmotic minipumps to
continuously infuse several doses of the 5.1 kDa poly(acrylic
acid) (pAA5.1) into rats fed a diet which causes renal calcium
oxalate crystal deposition. Although kidneys of rats receiving
the saline control contained calcium oxalate crystals,
measured by polarized light microscopy, those of animals
given pAA5.1 had significantly lower numbers of crystals in
various zones of the kidney. Delivery of pAA5.1 to urine was
confirmed by measuring excretion of infused biotinylated
pAA5.1. Both the derivatized and unlabelled pAA5.1 had the
same effects on crystallization in vitro. Our study shows that
acidic polymers hold promise as effective therapies for
kidney stones likely through prevention of calcium oxalate
crystal aggregate formation.
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Urinary macromolecules appear to influence kidney stone
formation at several of the steps in their formation. The
hypothesis tested in the studies reported in this article is that
manipulation of the interaction between urinary macro-
molecule and crystalline stone material can influence crystal
deposition in one experimental model of the initiation of
kidney stone formation.
The first step in stone formation is the nucleation
of crystalline components. This may occur in the lumens of
renal tubules, in the basement membranes of tubule cells, or
at both sites, perhaps depending on the type of stone or the
underlying conditions that predispose to stone formation.1,2
Whether growth of the solid phase is required for retention
within the kidney depends on several factors These include
whether the site of nucleation is within the tubule lumen or
outside of it, or whether a specific attachment mechanism to
cells or extracellular matrix is present for stone crystals. What
is obvious, however, is that such growth must occur for a
stone to achieve clinically a significant mass.
This growth appears to be largely a consequence of
aggregation of crystals that have nucleated individually in
tubular or interstitial fluid, or growth may result from
secondary nucleation of new crystals on the surface of those
previously formed, regardless of the site of initial crystal
fixation in the kidney. In particular, the site of fixation is
immaterial to this concept; it may occur either at the apical
membranes of tubule cells or within their basement
membranes. Inspection of scanning photomicrographs of
stones reveals their multicrystalline nature,3 as well as the
presence of a matrix that appears to act like a binding agent
akin to the function of Portland cement to bind together
silica in concrete. Stone matrix contains numerous urinary
macromolecules; the most prominent have been highly acidic
proteins and glycosaminoglycans.4
Acidic urinary macromolecules that have been studied
individually interact strongly with crystals and generally
inhibit crystal formation, especially those of calcium oxalate
(CaOx), in vitro.5–12 Synthetic polyanions have similar effects
on CaOx formation; however, polycations and neutral
polymers are, in general, ineffective.13–17 Among the synthetic
polyanions, those with carboxylate side chains are more
potent at inhibiting crystal formation than phosphoryl or
sulfonyl, in that order. The effects seem to be insensitive to
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the backbone of the molecule; however, charge group spacing
may be important. These synthetic polyanions affect several
processes in vitro that may have a bearing on stone formation.
Acidic polyanions inhibit attachment of calcium oxalate
monohydrate (COM) to cultured inner medullary collecting
duct cells, change crystal habit from COM to calcium oxalate
dihydrate (COD) in spontaneous crystallization assays,
decrease step velocity of COM growth in constant composition
experiments, exhibit strong interaction with multiple crystal
surfaces by atomic force microscopy, and disaggregate COM
seed crystal aggregates in experiments employing particle
sizing.16,18 Poly(acrylic acid) (pAA) is among the most potent
of these molecules19 (unpublished data). The specific purpose
of the current studies was to determine whether infusions of
5.1 kDa pAA (pAA5.1) are effective in preventing CaOx crystal
deposition in rats fed with ethylene glycol.
RESULTS
Inhibition of crystal deposition
Figure 1 shows the results of the pAA5.1 infusions at various
rates into rats on a crystal inducing diet (CID; 0.8% ethylene
glycol with 1% NH4Cl in tap water) compared with controls
on the same diet receiving only saline infusions. With saline
alone, tissue sections of the rat kidneys showed significant
crystal deposition in all three zones of the kidney.
Presumably, these were largely comprised of COM, as they
could be visualized with partially polarized light. Using
similar feeding schedules, we and others20,21 have induced
COM deposition that has been verified by elemental or
crystallographic techniques. Rates of pAA5.1 infusion of
50–300 mg/h inhibited COM deposition significantly. At the
rates tested, the degree of inhibition was between 81 and
98%, depending on the anatomical zone (cortex, outer
medulla, or inner medulla) of the kidney examined, and was
without clear dose dependence. Lower infusion rates of
pAA5.1 did not differ from saline controls, although the 10
and 20 mg/h rates showed a trend toward inhibition (results
not shown).
The rats infused with pAA and receiving the CID did not
differ from saline controls on the same diet in either plasma
Ca or creatinine concentrations or urinary excretions of
either calcium or oxalate (Table 1).
Properties of biotinylated pAA5.1 in vitro
Bt- pAA5.1, 1 mg/ml, mimicked the effects of unlabeled pAA5.1
in promoting crystallization of COD over COM, inducing
B85% COD compared with 100% COM without the
polymer, as determined by optical microscopy.22 In addition,
in a static aggregation assay, 0.5 mg/ml (equivalent to 100 nM)
bt-pAA5.1 produced the same amount of disaggregation of
COM seed crystals (RD¼ 0.73, where a value of o1.0
indicates disaggregation and 41.0 indicates aggregation)
comparable with unmodified pAA5.1 (RD¼ 0.74).
Recovery and properties of infused bt-pAA5.1
We administered bt-pAA5.1 by osmotic minipump at 10 mg/h
to four rats. On day 9, the rats had a mean urinary bt-pAA5.1
excretion of 142±94 mg, which is equivalent to a bt-pAA5.1
concentration of B500 nM. Urine from two rats given tap
water that were infused with 50 mg/h was added to the COM
aggregation assay in an amount normalized to 10 mg of
creatinine and proved effective at disaggregating seed crystal.
This was the case both in a rat whose urine before infusion
promoted aggregation and in a rat whose baseline urine
inhibited aggregation (Figure 2). Progressive dilution of
the urine collected from the rat whose urine promoted
aggregation before the infusion, which provided progressively
decreasing concentrations of bt-pAA5.1, demonstrated
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Figure 1 | Effect of pAA5.1 on retention of CaOx in kidneys of
rats fed CID. Values are means±s.e. of control rats receiving
saline (Cont) through minipumps or rats receiving the indicated
infusion rates of pAA5.1. Analysis of variance indicates an F statistic
of 3.01 with a P-value of 0.03. The values for the groups receiving
pAA5.1 are all significantly different from Cont Pp0.005. None of
the mean values for the different pAA5.1 infusion groups were
significantly different from the others.
Table 1 | Plasma and urine creatinine, calcium, and oxalate values of rats on CID
Plasma Urine
Creatinine (mg/100 ml) Calcium (mg/100 ml) Calcium/creatinine (mg/mg) Oxalate/creatinine (mg/mg)
Saline controls 0.69±0.06 (21) 10.3±0.2 (21) 0.18±0.01 (7) 0.71±0.08 (7)
pAA5.1 0.61±0.06 (30) 10.6±0.1 (30) 0.24±0.05 (7) 0.54±0.13 (7)
Values are means±s.e. for (N); the values for rats receiving saline in minipumps were not different from those receiving pAA5.1. Plasma creatinine and calcium concentrations
did not differ among the various rates of infusion of pAA5.1 (not shown), so results have been combined. Urine pAA5.1 calcium and oxalate values are obtained from animals
infused with the 300 mg/h dose.
920 Kidney International (2008) 74, 919–924
o r i g i n a l a r t i c l e JG Kleinman et al.: Poly(acrylic) acid prevents calcium oxalate deposition
significant disaggregation of seed crystal down to somewhat
below a concentration of 1 nM (Figure 3).
DISCUSSION
The process of formation of kidney stones includes nuclea-
tion of stone-constituent crystals, which may occur either
within the tubules or in the interstitium. In the case of
intratubular nucleation, some investigators have proposed
and developed evidence for a specific attachment process to
renal tubular cells.23–27 Alternatively, crystals may enlarge
individually through growth or may aggregate with others,
resulting in fixation within the kidneys on the basis of size
alone.28 In either case, whether fixation occurs at the level of
the individual crystal or small crystal aggregates, further
enlargement to clinically significant size appears to take place
through addition of free-floating crystals or nucleation of
crystals secondarily on the surface of aggregates already fixed
to tissue.
As was pointed out in the introduction, pAA shares many
of the properties of endogenous urinary acidic macromole-
cules that have been shown to influence crystal formation,
either in vitro or, by inference, in animal experiments.20,29
These include both inhibition of attachment of individual
crystals and the aggregation of preformed crystals. If, as
proposed above, attachment and aggregation are critical
processes that lead to crystal retention, pAA might be
expected to prevent crystal retention.
The studies reported in this communication demonstrate
that pAA5.1 infusions into rats fed with a mixture of ethylene
glycol and NH4Cl prevent the accumulation in their kidneys
of CaOx crystals. Ethylene glycol administration in rodents
has been used as an experimental model for the initiation of
kidney stones for a number of decades.21 It has been
criticized on a number of bases, including that it induces
injury in kidneys and that it is more relevant to primary
hyperoxaluria rather than idiopathic or hypercalciuric stone
disease. However, if given in sufficiently small amounts,
ethylene glycol has been shown to induce crystalluria and
CaOx deposition in rodent kidneys without inducing
hyperoxaluric renal failure, although enzymuria and tubular
damage is likely present.21,30 In the studies reported here, at
least with regard to glomerular filtration, there did not
appear to be significant renal damage, as the serum creatinine
values in both control and experimental groups were not
different from those of untreated rats.
Whether pAA5.1 prevents crystal deposition by inhibiting
crystal aggregation or by weakening its attachment to renal
epithelial cells cannot be ascertained from these studies;
however, in vitro assays show evidence that the excretion of
pAA5.1 reaches a sufficient level to influence aggregation. The
studies with pAA5.1 labeled with biotin suggest that pAA5.1 is
excreted in the urine in amounts sufficient to confer on the
urine the capacity to disaggregate COM seed crystals in vitro
if not already present, specifically, in a rat whose urine
promoted aggregation before the infusion. In a rat that was
already excreting urine that disaggregated COM seed crystals,
the bt-pAA5.1 infusion led to excretion of urine with slightly
greater disaggregating ability.
The effect does not appear to be explainable by effects of
pAA5.1 on renal delivery of calcium, as there were no
differences between saline controls and groups infused with
pAA5.1 that were both on the CID in their plasma creatinine
or calcium concentrations. There were also no differences
between these controls and experimental groups in urinary
excretion rates of calcium or oxalate. Whether pAA5.1 in
urine can antagonize other toxic effects of oxalate on tubule
cells that could be responsible for inhibiting CaOx deposition
was not examined.
Finally, on the basis of global observation of the animals,
as well as the plasma creatinine values, there does not appear
to be any overt short-term toxicity to pAA5.1. On the basis of
its chemical structure, it is not likely that it is metabolized to
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Figure 2 | Effect of urine from two rats infused with Bt-pAA5.1
at 50 lg/h on COM aggregation. Urine collected on the day
before the infusion (Day 0) as well as on Day 7 and/or Day 9. The
urine was added to an in vitro aggregation assay, as described in
the Methods section, in amounts containing 10mg of creatinine.
Values are RD, the ratio of the final average particle diameter to
the diameter of the initial seed COM crystal.
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Figure 3 | Effect of urinary Bt-pAA5.1 on COM aggregation.
Urine before the Bt-pAA5.1 infusion in rat 2 (’) shown in the
previous figure was tested in an amount containing 10 mg of
creatinine; the day-9 urine was diluted from its measured
concentration to the concentrations indicated on the abscissa.
The trend line remains flat to the highest concentration studied
(50 nM), which is not shown. Values are RD, the ratio of the final
average particle diameter to the initial seed COM crystal.
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any significant extent in the body. Further studies will have to
be performed to assess whether recovery in urine is complete
or whether pAA5.1 is sequestered at various sites in the body.
Finally, oral absorption of pAA5.1 will need to be tested.
However, even if pAA5.1 is not suitable as a therapeutic agent
for the prevention of kidney stones, the study results reported
here suggest that similar compounds hold such promise.
MATERIALS AND METHODS
Experimental animals
Male Sprague–Dawley rats (Charles River Laboratories Inc.,
Wilmington, MA, USA), weighing approximately 200 g when
delivered, were used in the study. Rats were housed in the Veterinary
Medical Unit (Veterans Affairs Medical Center, Milwaukee, WI,
USA) and were given regular drinking (tap) water and regular rat
chow, Lab Diet 5001 Rodent Diet (PMI Nutrition International,
LLC, Brentwood, MO, USA). The rats were acclimatized for
approximately 1 week before use. Protocols were approved by the
Animal Care Committee.
Surgical techniques
Rats were placed in individual cages and made to fast overnight.
Alzet 1 ml/h osmotic minipumps, Model 2001 (Durect Corporation,
Cupertino, CA, USA) were filled as per manufacturer’s instructions
with pAA5.1 (Fluka/Sigma, St Louis, MO, USA) or 0.9% saline
(Baxter Healthcare Corporation, Deerfield, IL, USA). Rats were
anesthetized with 40 mg of pentobarbital (Abbott Laboratories,
Abbott Park, IL, USA) per kg body weight by intraperitoneal
injection. Employing sterile technique, the filled pumps were
subcutaneously implanted along the upper left side of the backs of
the rats. The rats were monitored during recovery from anesthesia
and housed in regular cages without bedding. Paper towels were
placed in the cages for nesting purposes. The next day, the rats were
transferred to fresh cages with bedding.
Inhibition of crystal retention
The osmotic minipumps were filled with either varying concentra-
tions (1–300mg/ml) of pAA5.1 or saline (experimental rats: n¼ 3 for 1
and 100 mg/ml pAA5.1; n¼ 2 for 10 mg/ml; n¼ 4 for 20, 50, and
200mg/ml; and n¼ 10 for 300mg/ml; saline control rats: n¼ 21). As
the minipumps deliver fluid at a rate of 1 ml/h, the indicated
concentrations are equivalent to delivery of these amounts of this
agent per hour. The minipumps are nominally of 1-week duration,
but contain enough volume for at least 9 days. On the day following
implantation of minipumps, the rats were placed on the CID, 0.8%
ethylene glycol (Sigma, St Louis, MO, USA) with 1% NH4Cl
(Sigma) in tap water for 8 days. The rats were fed with regular rat
chow. A quantitative urine collection was obtained over 24 h ending
on the day of killing.
Tissue harvest and processing
At the end of the experiments, the rats were anesthetized and then
killed by pneumothorax/exsanguinations. Blood was collected
through cardiac needle stick and transferred to lithium heparin
tubes (BD, Franklin Lakes, NJ, USA). The blood was then
centrifuged for 15 min at 2800 r.p.m. and 4 1C to isolate plasma,
which was then stored at 80 1C until being tested for creatinine
and calcium. Kidneys were harvested and then rinsed in chilled
phosphate-buffered saline, pH 7.4 (Sigma), that had been saturated
with calcium and oxalate (PBS-CaOx) by overnight incubation with
0.1 mg COM crystals/ml and then filtered to remove the crystals.
The kidneys were decapsulated, rinsed as before, sliced in 2–3 mm
sections, rinsed again, then immersion-fixed for 18–24 h at room
temperature in 10% formalin in PBS-CaOx. Kidney slices were then
rinsed for three times in chilled PBS-CaOx, kept at 4 1C for 18–72 h
in 20% sucrose (Sigma) in 0.1 M PBS-CaOx, placed in 20% gelatin
(Fisher Scientific, Pittsburgh, PA, USA) overnight at room
temperature, and after removal from the gelatin, the tissue was
stored frozen at 80 1C. Cryosections (10 mm thickness) were cut
from the tissue samples using an UltraPro 5000 Cryostat
(Vibratome, St Louis, MO, USA). The pumps were removed from
the animals and the remaining solution was removed and measured
to ensure that the pumps had released their contents.
Analysis of blood and urine
Plasma calcium and creatinine testing was performed using the ACE
Clinical Chemistry System autoanalyzer (Alfa Wassermann Inc.,
West Caldwell, NJ, USA) in the Biochemical Core Laboratory,
Department of Physiology, Medical College of Wisconsin, Milwau-
kee, Wisconsin. Creatinine was measured using the Jaffe Reaction
(Alkaline Picrate) without Lloyd’s Reagent and reported as mg/
100 ml. Calcium was measured using Arsenazo III Dye and reported
as mg/100 ml for plasma.
Urinary ions were measured using a dual pump ICS-3000 ion
chromatography system equipped with two conductivity detectors,
UV detection (ICS-VWD), ion suppressors (CSRS or ASRS Ultra-
II), and an autosampler (Dionex, Sunnyvale, CA, USA). Cations
were separated on an IonPac CS12A column with guard column
using a 20 mN H2SO4 mobile phase (1 ml/min, 25 ml injection
volumes) over a 20 min period. Creatinine was detected in tandem
on this system with UV (A210) detection (Dionex Application Note
107). Oxalate was separated from other urinary anions using an
IonPac AS4A column with guard column employing a 1.7 mM
sodium bicarbonate, 2.0 mM sodium carbonate eluent system (2 ml/
min, 25 ml injection volumes) over a 30 min period (R. Holmes,
Wake Forest University, Winston-Salem, NC, USA, personal
communication). Detection limits for calcium, creatinine, and
oxalate using these methods were 62, 25, and 50 ng, respectively. IC
grade reagents were purchased through Sigma and diluted in
deionized water (X17.8 MO cm resistance). Anion and cation
standards were purchased from Dionex. Creatinine standards were
available from TECO diagnostics (Anaheim, CA, USA).
Crystal quantification
Crystals in the kidney cryosections were observed at a total
magnification of 260-fold under partially polarized light using a
Nikon Optiphot-2 microscope with a polarizing lens (Nikon,
Melville, NY, USA), SIT 66 camera (DAGE-MTI of MC Inc.,
Michigan City, IN, USA) and Sony Trinitron monitor (Sony
Corporation of America, New York, NY, USA). The planar area
occupied by the crystals was quantified using Image 1 software
(Universal Imaging Corporation, now part of Molecular Devices,
Sunnyvale, CA, USA). For each animal, randomly selected fields
(n¼ 6) of each kidney area (cortex, outer medulla, and inner
medulla) were imaged. The values were recorded as pixels (object
area).
Biotinylation of pAA5.1
PAA5.1 was biotinylated at a ratio calculated to provide only one
biotin for every molecule of acrylic acid biotin LC-hydrazide
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according to the manufacturer’s instructions (Pierce, Rockford, IL,
USA). The unincorporated label was removed using a PD10
desalting column (Bio-Rad, Hercules, CA, USA) equilibrated in
PBS and collected in 1 ml fractions. Positive fractions were assessed
using a dot blot with streptavidin-horseradish peroxidase detection
(see below) and the recovered amount was quantified by reference to
the absorption at 220 nm of known quantities of pAA5.1.
Biotinylated pAA5.1 (Bt-PAA5.1) detection and recovery
in rat urine
We administered bt-pAA5.1 by osmotic minipump at 10 mg/h to four
rats and at 50 mg/h in two rats on tap water without CID. Rat urine
samples were treated with 10% trichloroacetic acid (30 min on ice,
then centrifuged at 4 1C for 10 min at 15,000 r.p.m.) followed with a
cold acetone wash to decrease nonspecific sample signal. The
precipitates from the urine samples and parallel Bt-pAA5.1 standard
samples were reconstituted in PBS and loaded onto a dot blot
manifold using nitrocellulose membranes. The membrane was
stained for sample transfer and well integrity using Ponceau S (0.1%
Ponceau S, 3% TCA), washed with 0.1% Tween in Tris-buffered
saline, and blocked with 2% BSA–Tris-buffered saline for 1 h. Biotin
was reacted with streptavidin-horseradish peroxidase (1:10,000 in
2% BSA-Tris-buffered saline for 1 h). The membrane was extensively
washed (4 , Tris-buffered saline) and horseradish peroxidase was
detected by chemiluminescence (Femto-ECL, Pierce). The dot blot
image was acquired using an image station (IS2000 MMT, Kodak,
New Haven, CT, USA), and Kodak molecular imaging software was
used to quantify the signal in pixels.
In vitro COM aggregation assay
The biotinylated and unlabeled pAA5.1 were tested for their ability to
regulate COM aggregation by analysis of the particle size distribu-
tion changes of COM seed crystals added to a slightly supersaturated
solution of CaOx containing the particular compound, as described
previously.16 Specifically, 300mg of COM seed crystals are added to
5 ml of a solution of 0.25 mM CaCl2 and Na2C2O4 in 150 mM NaCl,
buffered to pH 7.5 with 10 mM HEPES (supersaturation1.1111), and
allowed to mix for 1 h at 37 1C. The slight supersaturation was
employed to assure that no dissolution occurred to skew the results.
Then, the particle size distribution of an aliquot of this mixture was
determined using the AccuSizer 780/SIS (Particle Sizing Systems,
Santa Barbara, CA, USA).
To determine the seed crystal particle size distribution, 15 mg of
COM crystals were added to 15 ml of sizing buffer (0.225 mM CaCl2,
0.225 mM Na2C2O4, 10 mM HEPES; 0.2 mm filtered) and measured in
duplicate. The sizing buffer was shown to cause neither significant
growth nor dissolution of the COM crystals for up to 1 h.
Aggregation data from these bulk crystallization methods were
expressed as RD, the ratio of the final weight average particle
diameter (Dw) for the particle size distribution to the Dw of the
COM seed crystals measured daily.
Statistical analyses
Values are expressed as mean±s.e. Statistical significance, defined as
P-valueo0.05, was calculated using the Student’s t-test for unpaired
data assuming unequal variances with Microsoft Office Excel 2003
(Microsoft Corporation, Redmond, WA, USA).
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